Sonnet Biotherapeutics Inc. (NASDAQ: SONN) stock gained by 1.32% at the last close while the SONN stock price rises by 9.89% in the pre-market trading session. Sonnet BioTherapeutics is a biotechnology-driven cancer firm with a patented platform for creating single or bispecific biologic medicines.
What is happening?
SONN announces the issuance of U.S. Patent number 11,028,166 entitled ‘Albumin Domain Fusion Protein’ by the United States Patent and Trademark Office. The patent covers the Fully Human Albumin Binding (FHAB) technique of Sonnet and comprises the therapeutic fusion proteins which use FHAB for the targeting and preservation of the tumor and which enable prolonged pharmacokinetics.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Pankaj Mohan, Founder, and CEO stated,
This intellectual property clearance is a crucial milestone that distinguishes Human Serum Albumin from any current or future rival technology that may use it. This serves as a strategic basis for their product pipeline future, as well as providing essential validation for their FHAB platform. SONN is very delighted to bring their distinctive and patent-protected innovation to patients through the development of their product pipeline.
The FHAB platform from Sonnet is made up of a single, completely human FHAB antibody fragment with a high affinity for binding to human albumin. The platform allows for the quick development of a variety of therapeutic biologics using off-the-shelf lock-and-load technology.
John Cini, Co-Founder, and CSO, stated:
FHAB technology offers a mono- or bi-specific mode of action to all Sonnet pipeline assets. The FHAB-derived candidates of Sonnet have demonstrated their reproductive efficiency when evaluated in vivo against several wild cytokines. FHAB shows better penetration in TMEs and increased delivery of payloads to the tumor through both passive and active transport modes, as well as increased pharmacokinetics, based on a linear structure that is adaptable.